Natalizumab and Anti-Natalizumab Antibody, DoseASSURE™ NTZ
Also known as: Anti-alpha4-integrin inhibitor, biologic therapeutic drug monitoring (TDM), biological monitoring, immunogenicity testing, Tysabri drug and antibody testing
Use
Provides natalizumab drug and anti-natalizumab antibody concentrations for pharmacokinetic and immunogenic assessment to optimize treatment. This test may be helpful in any patient on natalizumab therapy for multiple sclerosis, Crohn's disease or other conditions.
Special Instructions
Not provided.
Limitations
High serum biotin concentrations in patients taking biotin supplements may cause interference in this assay. Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection.
Methodology
Immunoassay (ECLIA)
Biomarkers
Anti-Natalizumab Antibody
AnalyteNatalizumab Drug Level
Analyte
LOINC Codes
- 103631-8 - Natalizumab Ser Ql IA
- 103631-8 - Natalizumab Ser Ql IA
- 103632-6 - Natalizumab Ab Ser IA-mCnc
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube.
Storage Instructions
Refrigerate or freeze.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant